Company: SMNR
Filing Date: 2025-04-02
Form Type: 10-K
Source: 0001213900-25-027319
Chunk: 1201

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-02
Form: 10-K
Item: Item 7A
Chunk 1201
---
 11, 2023, issued by Denali Capital Acquisition Corp. to FutureTech Capital LLC(3)
  
    10.15
     
    Convertible Promissory Note, dated July 10, 2024, issued by Denali Capital Acquisition Corp. to Denali Capital Global Investments LLC(8)
  
    10.16
     
    Convertible Promissory Note, dated August 9, 2024, issued by Denali Capital Acquisition Corp. to Scilex Holding Company(10)
  
    10.17
     
    Deferred Discount Agreement, dated as of November 20, 2023, by and among Denali Capital Acquisition Corp., Denali SPAC Holdco, Inc., US Tiger Securities, Inc., EF Hutton, division of Benchmark Investments, LLC and Craig-Hallum Capital Group LLC(6)
  
    10.18
     
    Termination Agreement, dated as of June 26, 2024, by and among Denali Capital Acquisition Corp., Longevity Biomedical, Inc. and Bradford A. Zakes, as seller representative(11)
  
    16.1
     
    Letter Regarding Change in Accountants (12)
  
    19.1*
     
    Insider Trading Policy
  
    21.1*
     
    List of Subsidiaries
  
    31.1*
     
    Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
  
    31.2*
     
    Certification of Principal Financial and Accounting Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
  
    32.1**
     
    Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
  
    32.2**
     
    Certification of Principal Financial and Accounting Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
  
    97.1